Name | oritavancin bisphosphate |
---|---|
Synonyms |
(1S,2R,18R,19R,22S,25R,28R,40S)-22-(2-Amino-2-oxoethyl)-2-[(3-amino-2,3,6-trideoxy-3-methyl-α-L-arabino-hexopyranosyl)oxy]-5,15-dichloro-48-{[2-O-(3-{[(4'-chloro-4-biphenylyl)methyl]amino}-2,3,6-t rideoxy-3-methyl-α-L-arabino-hexopyranosyl)-β-D-glucopyranosyl]oxy}-18,32,35,37-tetrahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26 .14.2.2.2.1.1.0~10,
Oritavancin Diphosphate |
Description | Oritavancin diphosphate is a novel semisynthetic glycopeptide antibiotic being developed for the treatment of serious Gram-positive bacterial infections. Target: AntibacterialOritavancin is a lipoglycopeptide.Oritavancin has completed clinical trials and submitted a new drug application for treatment of skin infections. |
---|---|
Related Catalog | |
References |
Molecular Formula | C86H103Cl3N10O34P2 |
---|---|
Molecular Weight | 1989.091 |
Exact Mass | 1986.517944 |
PSA | 736.12000 |
LogP | 6.85530 |
Storage condition | 2-8℃ |